<?xml version='1.0' encoding='utf-8'?>
<document id="31654788"><sentence text="Drug-drug interaction trials incompletely described drug interventions in ClinicalTrials.gov and published articles: an observational study." /><sentence text="The aim of the study was to evaluate the completeness of intervention description in ClinicalTrials" /><sentence text="gov and corresponding journal articles for registered and published drug-drug interaction (DDI) trials because complete and transparent description of interventions is particularly important for DDI" /><sentence text="" /><sentence text="Observational study of completed interventional trials on DDIs with up to two drugs within the Intervention registration element in ClinicalTrials" /><sentence text="gov until October 2015" /><sentence text=" We used the Template for Intervention Description and Replication items to assess the quality of intervention description in both ClinicalTrials" /><sentence text="gov Descriptive Information section and matching publications" /><sentence text=" Corresponding articles were identified in MarchÂ 2019" /><sentence text="" /><sentence text="The description of 1,180 drug interventions registered for 642 DDI trials mostly lacked information on the intervention provider (99" /><sentence text="7%), adherence strategies (99" /><sentence text="2%), procedure (83" /><sentence text="8%), location (71" /><sentence text="3%), and dosage form (60" /><sentence text="7%)" /><sentence text=" Generic name (82" /><sentence text="5%), dose (70" /><sentence text="8%), and duration of administration (65" /><sentence text="6%) were most frequently reported" /><sentence text=" Among 51 trials that had data reported both in ClinicalTrials" /><sentence text="gov and publication, 60" /><sentence text="8% were in phase 1" /><sentence text=" Less than half of 96 interventions had clear and matching description of dosage form, procedure, and route of administration in both sources" /><sentence text="" /><sentence text="DDI trials did not sufficiently report components required for complete intervention description" /><sentence text=" Further improvements in ClinicalTrials" /><sentence text="gov registration requirements, including phase 1 trials, and more stringent publishing requirements for essential data on drug interventions, are needed to prevent patient risk in clinical practice regarding concomitant medication use" /><sentence text="" /></document>